- Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
May 7, 2026 · zacks.com
Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026
Apr 28, 2026 · businesswire.com
VANCOUVER, B.C. & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accom.
- ALPHA COGNITION (NASDAQ: ACOG) TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON THURSDAY, MAY 14, 2026
Apr 28, 2026
VANCOUVER, B.C. & DALLAS--(BUSINESS WIRE)--ALPHA COGNITION INC. (NASDAQ: ACOG), A BIOPHARMACEUTICAL COMPANY DEDICATED TO ADVANCING TREATMENTS FOR NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT IT WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE ON THURSDAY, MAY 14, 2026, AT 4:30 P.M. ET, AFTER MARKET CLOSE. THE COMPANY WILL ISSUE A PRESS RELEASE DETAILING ITS FIRST QUARTER FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS ON THAT DATE. THE FINANCIAL RESULTS AND ACCOM.
- Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences
Apr 27, 2026 · businesswire.com
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2.
- ALPHA COGNITION INC. TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES
Apr 27, 2026
VANCOUVER, BRITISH COLUMBIA & GRAPEVINE, TEXAS--(BUSINESS WIRE)--ALPHA COGNITION, INC. (NASDAQ: ACOG) (“ALPHA COGNITION”, “ACI”, OR THE “COMPANY”), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR DEBILITATING NEURODEGENERATIVE DISORDERS, TODAY ANNOUNCED THAT MICHAEL MCFADDEN, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN THREE INVESTOR CONFERENCES IN MAY. EVENT DETAILS ARE AS FOLLOWS: MARKET MOVERS INVESTOR SUMMIT FORMAT: PRESENTATION AND 1X1 MEETINGS DATE/TIME: TUESDAY, MAY 5 AT 2.
- Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig
Apr 20, 2026 · businesswire.com
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate s.
- ALPHA COGNITION STRENGTHENS ITS BOARD OF DIRECTORS WITH APPOINTMENT OF BETHANY SENSENIG
Apr 20, 2026
VANCOUVER, BRITISH COLUMBIA & DALLAS--(BUSINESS WIRE)--ALPHA COGNITION INC. (NASDAQ: ACOG) (“ALPHA COGNITION”, OR THE “COMPANY”), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING NOVEL THERAPIES FOR DEBILITATING NEURODEGENERATIVE DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF BETHANY SENSENIG TO ITS BOARD OF DIRECTORS, EFFECTIVE APRIL 15, 2026. MS. SENSENIG BRINGS DECADES OF LEADERSHIP EXPERIENCE ACROSS THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES, WITH DEEP EXPERTISE IN FINANCE, CORPORATE S.
- Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 15, 2026 · businesswire.com
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on April 14, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 20,000 shares of common stock to a.
- ALPHA COGNITION REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Apr 15, 2026
VANCOUVER, BRITISH COLUMBIA & GRAPEVINE, TEXAS--(BUSINESS WIRE)--ALPHA COGNITION INC. (NASDAQ: ACOG) (“ALPHA COGNITION”, “ACI”, OR THE “COMPANY”), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR DEBILITATING NEURODEGENERATIVE DISORDERS, TODAY ANNOUNCED THAT ON APRIL 14, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE “COMPENSATION COMMITTEE”) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE 20,000 SHARES OF COMMON STOCK TO A.
- Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock?
Apr 2, 2026 · zacks.com
Alpha Cognition Inc. (ACOG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.